Last $57.35 USD
Change Today +0.33 / 0.58%
Volume 657.8K
TEVA On Other Exchanges
New York
Tel Aviv
As of 9:55 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

Petach Tikva, 49131


Phone: 972 3 926 7267

Fax: 972 3 923 4050

e Granulocyte Colony Stimulating Factor (G-CSF) medicines that stimulate the production of white blood cells and are primarily used to reduce the risk of infections in oncology patients receiving chemotherapy. Granix (short-acting G-CSF) is approved in the United States and is approved via a Biologics License Application by the FDA in 2012 and launched in 2013. The product is also approved and available in Japan and certain other Rest of the World (ROW) markets. In December 2014, the FDA also approved Granix injection for self-administration by patients and caregivers. Lonquex (long-acting G-CSF) is a G-CSF with the active ingredient lipegfilgrastim, a novel glycoPEGylated (PEG; polyethylene glycol) filgrastim molecule. Women’s Health The company’s women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel), and Zoely along with other local products that are marketed in the United States, Europe and ROW. Plan B One-Step OTC/Rx (levonorgestrel) is an emergency oral contraceptive which consists of a single tablet dose of levonorgestrel for emergency contraception. ParaGard T380 A (intrauterine copper contraceptive) is a non-hormonal intrauterine contraceptive marketed in the United States. Other Activities The company’s other activities comprise its OTC business. Consumer Healthcare Joint Venture PGT Healthcare (PGT) is its consumer healthcare joint venture with The Procter & Gamble Company. The joint venture includes its OTC medicines and vitamins, minerals and food supplements (VMS). PGT manufactures and markets approximately 200 consumer healthcare brands in 70 countries worldwide. Its portfolio includes cough and cold brand Vicks, Germany’s OTC brand ratiopharm, and other brands. Strategy The company seeks to capitalize on its advantages, including the largest generic medicines business in the world, a focused specialty business, a unique OTC business and its integrated R&D and API capabilities to provide patients with integrated, outcome-focused solutions. The key elements of its strategy consist of the following: solidifying its foundation and driving organic growth; focusing on key growth markets; maintaining Copaxone and other key specialty products; solidifying leadership positions in core therapeutic areas; pursuing strategic business development initiatives; and executing on cost reduction program. History Teva Pharmaceutical Industries Limited was founded in 1901.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $57.35 USD +0.33

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.38 USD -0.125
Actavis plc $295.27 USD +3.91
AstraZeneca PLC 4,475 GBp +5.50
Eli Lilly & Co $70.90 USD +0.73
Valeant Pharmaceuticals International Inc C$250.58 CAD +4.31
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVA Industry Range
Price/Earnings 16.0x
Price/Sales 2.4x
Price/Book 2.1x
Price/Cash Flow 17.9x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at